NTRK2 (TrkB) is a receptor tyrosine kinase essential for nervous system development and function. The receptor binds brain-derived neurotrophic factor (BDNF) and neurotrophin-4, undergoing homodimerization and autophosphorylation upon ligand binding 1. NTRK2 regulates neuron survival, proliferation, differentiation, and synaptic plasticity through multiple downstream cascades: the SHC1/FRS2/SH2B-mediated GRB2-Ras-MAPK pathway promotes neurite outgrowth and differentiation, while the Ras-PI3K-AKT axis supports growth and survival 1. PLCG1 signaling controls synaptic plasticity, learning, and memory through protein kinase C and NF-κB-dependent transcription 1. Beyond neuronal development, NTRK2 has emerging therapeutic relevance. NTRK2 gene fusions drive various cancers and respond to TRK inhibitors including entrectinib and larotrectinib with response rates exceeding 75% 23. In gliomas, BDNF-TrkB signaling promotes malignant synaptic plasticity and tumor progression; TrkB blockade substantially extends survival in pediatric glioblastoma models 4. Psychedelics including LSD directly bind TrkB with high affinity and promote antidepressant-like effects through BDNF signaling independent of 5-HT2A activation 5. Additionally, TrkB agonist antibodies restore fertility in premature ovarian failure models 6 and promote alveolar epithelial regeneration after lung injury 7, positioning NTRK2 as a versatile therapeutic target across diverse pathologies.